



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

PCT/EP200 4 / 0 5 1 9 9 7

02.09.04

REC'D 07 OCT 2004

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03405635.8

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk

BEST AVAILABLE COPY



PCT/EP200 4 / 0 5 1 9 9 7

02.09.03

Anmeldung Nr:  
Application no.: 03405635.8  
Demande no:

Anmeldetag:  
Date of filing: 02.09.03  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Fussenegger, Martin  
Bergacker 76  
8046 Zürich  
SUISSE  
Weber, Wilfried  
Lachenacker 16  
8049 Zürich  
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Regulatable gene expression in mammalian cells and mammals

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

G12N5/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT RO SE SI SK TR LI

## Regulatable gene expression in mammalian cells and mammals

### Field of the invention

5 The invention relates to mammalian cells and non-human mammals harboring a protein which transactivates transcription from natural or chimeric promoters in response to compounds being gaseous or liquid at cultivation temperature or at the body temperature of the mammal. Furthermore, the invention relates to a method of using such proteins to regulate gene expression in mammalian cell culture or non-human mammals in response  
10 to regulating compounds being gaseous or liquid at cultivation temperature or at the body temperature of the mammal. The invention further discloses nucleic acids useful for constructing said mammalian cells and mammals.

### Background of the invention

15 Current technologies for regulating gene expression in mammalian cells or mammals require administration of small-molecule drugs, typical examples of which are antibiotics, hormone analogues or immunosuppressive agents (see e.g. US Pat. No. 6,287,813, US Pat. No. 6,379,945, US Pat. No. 6,187,757, US Pat. No. 5,464,758). These  
20 compounds are often difficult to remove from the cell and the cell's environment after administration, which impedes reversion of the gene expression status. Also, regulating small-molecule drugs elicit long-term side effects on human or animal organisms, which raises safety concerns in gene therapy trials.

25 Both limitations can be overcome by novel gene regulation technologies, which are responsive to gaseous or volatile liquid compounds since said compounds can rapidly be removed from the cell and its environment by stripping with gases like air. Recently, gas-inducible systems have been developed for fungal (US Pat. No. 5,710,021) or plant (US Pat. No. 6,380,463) cells, where gene expression can be adjusted in response to  
30 ketones or aldehydes including the volatile acetaldehyde (boiling point: 21°C) or to other compounds, which are metabolized to those regulating compounds, for example ethanol. The aforementioned gene regulation systems for fungal and plant cells are based on the *Aspergillus nidulans*-derived AlcR transcription factor, which, in the presence of acetaldehyde and related compounds, activates transcription from promoters containing  
35 specific operator sites derived or homologous to those found in the *A. nidulans* P<sub>alcA</sub>

promoter. In the absence of regulating compounds, AlcR-mediated transactivation is prevented and gene expression remains silent.

### Summary of the invention

5 The present invention is directed to mammalian cells and non-human mammals harboring transcription factors responsive to compounds being liquid or gaseous at the cultivation temperature of said mammalian cells or at the body temperature of said non-human mammals, and to mammalian cells and non-human mammals harboring the  
10 corresponding responsive promoters. The invention is further directed to a method for adjusting gene expression in mammalian cells or non-human mammals by addition or removal of regulating compounds to the cell or mammal and its environment, whereby the regulating compounds are gaseous or liquid at the cultivation temperature of said cell or the body temperature of said non-human mammal. In another embodiment, the invention  
15 is directed to isolated nucleic acids useful for construction of said mammalian cells.

### Brief description of the Figures

20 Figure 1: Mode of function of the mammalian regulation system responsive to ketones or aldehydes like acetaldehyde.

Figure 1A: Expression vector for AlcR. The alcR gene (A) encoding the *Aspergillus nidulans*-derived AlcR protein is expressed under control of the simian virus 40-derived promoter ( $P_{SV40}$ ). Transcription is terminated by a polyadenylation site (pA).

Figure 1B: The responsive promoter encodes an AlcR-specific operator site (OP) fused to  
25 a minimal promoter ( $P_{min}$ ) followed by a gene of interest (goi) and a poly-adenylation site (pA).

Figure 1C: In the presence of gaseous or liquid regulating compounds (+RC), AlcR binds OP and activates  $P_{min}$  resulting in expression of a gene of interest (goi).

Figure 1D: In the absence of regulating compounds (-RC), AlcR binding is prevented and  
30 expression of a gene of interest (goi) remains silent.

Figure 2: Gene expression in response to acetaldehyde in mammalian cells using the *Aspergillus nidulans*-derived gene regulation system.

CHO-K1, BHK-21 and HeLa cells are transfected with the AlcR expression plasmid  
35 pWW195 and the corresponding promoter construct pWW192 driving expression of the

reporter gene SEAP (human placental secreted alkaline phosphatase). Transfected cells are seeded into 96-well plates and acetaldehyde (24  $\mu$ l/l) is applied to the first well of each row (well No. (WN) 1). Following incubation for 48 hours, relative SEAP production (in % relative to WN 1) is quantified in all wells.

5

Figure 3: Gene expression in response to gaseous inducing compounds contained in tobacco smoke.

CHO-K1 cells are transfected with the AlcR expression plasmid pWW195 and the corresponding promoter construct pWW192 driving expression of the reporter gene SEAP (human placental secreted alkaline phosphatase). Transfected cells are incubated in atmospheres containing different concentrations of tobacco smoke (S, in % v/v) for 48 hours prior to quantification of SEAP production in the cell culture medium (in U/l: units per liter, 1 U corresponds to the hydrolysis of 1  $\mu$ mol para-nitrophenylphosphate per min, Berger et al., 1998. *Gene* 66, 1-10).

15

Figure 4: Smoke-adjustable gene expression in mice.

CHO-K1 cells engineered with the AlcR expression plasmid pWW195 and the corresponding promoter construct pWW192 driving expression of the reporter gene secreted alkaline phosphatase (SEAP) are microencapsulated in alginate-poly-L-lysine-alginate capsules and intraperitoneally implanted into mice. Mice are exposed to different tobacco smoke concentrations (S, in % v/v) for 72 hours with smoke renewal every 12 hours prior to quantification of SEAP serum levels in mice (in mU/l).

25

#### Detailed description of the invention

For the purpose of the invention, a regulating compound (RC) is any compound or compound mix, which is gaseous or liquid at cultivation temperature of mammalian cells or at the body temperature of non-human mammals, and which directly or indirectly interacts with a responsive transcription factor (RTF) and thereby modulates transactivation activity of promoters harboring at least one OP operator site, to which said RTF can bind. The RC can be, as non-limited examples, selected from one of the following groups: ketones, aldehydes, alkanes, haloalkanes, alcohols, esters, amines and ethers like, for example and without limitation, ethanol, methylamine, ethylamine, n-propylamine, n-butylamine, n-pentylamine, n-hexylamine, benzylamine, 2-butanone, ethanol, n-propanol, n-butanol, 2-propanol, 2-butanol, L-threonine, 2-methylbutyr-

35

aldehyde, acetaldehyde, propanal, acetone, 2-butanone, 2-pentanone, 3-pentanone, cyclohexanone, glycoaldehyde, glyoxal, glyoxylate, ethylene glycol, ethanolamine, ethyl acetate, ethyl ether, and dicyclopropylketone.

- 5 For the purpose of the invention, a responsive transcription factor (RTF) is any polypeptide, which modulates transcription activity of OP-containing promoters in response to direct or indirect interaction with an RC molecule. The modulation of transcription activity mediated by RTF in response to RC is either caused by altered binding characteristics of RTF to OP-containing promoters or by interaction of RC with
- 10 RTF in a way that RTF alters its transactivation potential, for example via conformational changes. The RTF protein may comprise proteins identical to, derived from or related to proteins naturally encoded by prokaryotes or eukaryotes, either on the chromosome or an episome.
- 15 For the purpose of the invention, the operator sequence (OP) may comprise a naturally occurring polynucleotide sequence or a polynucleotide sequence derived from a naturally occurring polynucleotide sequence, which can be bound by an RTF either constitutively or in an RC-dependent way.
- 20 By an RTF comprising proteins being "derived from" naturally occurring proteins is meant, in this context, that the RTF comprises protein domains that contain amino acid substitutions, preferably conservative amino acid substitutions, but remain at least 70 %, preferably 80%, and more preferably 90% or more identical to the naturally occurring proteins at the amino acid level.
- 25 By an RTF comprising proteins "related to" naturally occurring proteins is meant, for purposes of the invention, that the polynucleotide sequence which encodes the amino acid sequence of the RTF protein hybridizes to a naturally occurring polynucleotide sequence encoding a naturally occurring protein under at least low stringency conditions,
- 30 more preferably moderate stringency conditions, and most preferably high stringency conditions.

"Conservative substitution" is known in the art and is described e.g. by Dayhof, M. D., 1978, *Nat. Biomed. Res. Found.*, Washington, D.C., Vol. 5, Sup. 3. Genetically encoded amino acids are generally divided into four groups: (1) acidic = aspartate and glutamate;

35

(2) basic = lysine, arginine, and histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, and tyrosine. Phenylalanine, tryptophan and tyrosine are also jointly classified as aromatic amino acids. A substitution  
5 in a protein of one amino acid classified in a particular group by another amino acid in the same group is generally regarded as a conservative substitution.

By an operator sequence (OP) "derived from" a naturally occurring polynucleotide sequence is meant, in this context, that the polynucleotide sequence of the OP contains  
10 base changes or modified nucleotides compared to the naturally occurring polynucleotide, but still can bind the RTF either constitutively or in an RC-dependent way.

The present invention is directed to mammalian cells comprising an RTF and a corresponding OP binding partner, which may be functionally linked to promoters or  
15 fragments thereof.

Particular pairs of RTF and OP binding partners are, for example, the *Aspergillus nidulans* AlcR protein (Flipphi et al., 2002, *Biochem J* 364, 25-31), which binds to the corresponding OP operator sequence (for example Genbank Accession No. S47331,  
20 nucleotides 30-308) in response to the addition of RC molecules as mentioned hereinbefore and to those described in Flipphi et al. (2002, *Biochem J* 364, 25-31) and the references therein; and the *Pseudomonas putida (oleovorans)* AlkS protein (Smits et al., 2001, *Plasmids* 46, 16-24), which binds to its corresponding OP binding partner derived from the P<sub>albB</sub> promoter in response to RC molecules as described hereinbefore.

25 The invention also extends to any RTF protein and the specific OP binding partner which may be found, for example by sequence database searching for proteins derived from or related to known RTF proteins using e.g. a BLAST (Altschul et al., 1997, *Nucleic Acids Res.* 25, 3389-402) computer program.

30 The RTF may be an assembly of different protein domains, which may comprise either artificially designed sequences or sequences derived from or related to naturally occurring sequences. In particular, the RTF may comprise protein domains which either activate or repress transcription of promoters functionally linked to OP binding sites. Activating  
35 domains useful for the present invention are, for example, the Herpes simplex VP16

domain or minimal versions thereof, and activating domains derived from or related to GAL4, p65, CTF/NF1, AP2, ITF1, ITF2, Oct1 and Spl. Repressing protein domains may be derived from or related to, for example, the v-erbA oncogene product, the thyroid hormone receptor, the *Drosophila* Krueppel protein, the KRAB protein domain, the  
5 Ssn6/Tup1 protein complex, the SIRI protein, NeP1, TSF3, SF1, WT1, Oct-2.1, E4BP4 and ZF5. Other repressing or activating polypeptides as listed in US Pat. No. 6,287,813 and those to be found according to the references cited therein are also within the scope of this invention.

10 In another preferred embodiment the invention is directed to non-human mammals comprising mammalian cells containing an RTF and a corresponding OP binding partner, which may be functionally linked to promoters or fragments thereof.

The invention is further directed to a method of using a mammalian cell or a non-human  
15 mammal containing an RTF and the corresponding OP binding partner for modulating gene expression in those organisms in response to the exogenous or endogenous administration of RC molecules. Therefore, the gene of interest may be fused downstream of a natural occurring or artificial promoter or a promoter fragment containing at least one OP site. This genetic construct is transferred into a mammalian cell or a non-  
20 human mammal also containing an expression vector for an RTF protein. The method comprises administration of RC molecules either via the gas phase or directly into the cultivation medium or the mammal in liquid form resulting in a modulated transactivation potential of RTF or in a changed interaction between RTF and OP leading to changed expression levels of the gene of interest. Additionally, the RC can be administered  
25 indirectly as a precursor compound, which is metabolized *in situ* to the active RC form.

The gene of interest may be any artificial or naturally occurring gene, either endogenous or exogenous to the mammalian cell, and may be, for example, the gene encoding SEAP, a fluorescent protein, human growth hormone, alpha-interferon, beta-interferon, gamma-  
30 interferon, insulin, erythropoietin, tissue plasminogen activator, DNase, a monoclonal antibody, Factor VIII, Factor VII, HAS, IL-2, glucagons, EGF, GCSF, GMCSF, thrombopoietin, gp160, HbSAg, or any tumor suppressor gene. The gene product can also be any protein interfering with absorption, distribution, metabolism or excretion of compounds contained in tobacco smoke, like nicotine.



The invention is further directed to isolated nucleic acids for expression of RTF in mammalian cells, said nucleic acids comprising a sequence coding for RTF under control of a constitutive or regulatable promoter functional in mammalian cells, and to isolated nucleic acids containing OP sequences functionally linked to promoters or promoter fragments functional in mammalian cells. The isolated nucleic acids may further comprise sequences useful for constructing viral vectors, like, for example, those based on or related to adenoviruses, adeno-associated viruses, retroviruses, alphaviruses, papillomaviruses, and picornaviruses.

- 10 The invention having been described, the following examples are offered by way of illustration and not limitation.

Example 1: Construction of a gas-inducible expression system for mammalian cells.

- 15 A gas-inducible expression system for mammalian cells is constructed based on the *Aspergillus nidulans* AlcR- $P_{AlcA}$  interaction responsive to small molecular compounds of the aldehyde and ketone class like acetaldehyde, which are gaseous at mammalian cell cultivation temperature (boiling point: 21°C) or at the body temperature of non-human mammals comprising those mammalian cells.

- 20 The responsive transcription factor AlcR is cloned under control of the simian virus 40 promoter ( $P_{SV40}$ ) by excising alcR (EcoRI/SalI) from an alcR cDNA containing vector (Flippi et al., 2002. *Biochem J* 364, 25-31) and cloning it (EcoRI/XhoI) into pWW75 (Weber et al., 2002. *Biotechnol Bioeng* 80, 691-705), thereby resulting in plasmid pWW195.

- 25 A responsive promoter is designed by cloning the AlcR-specific OP site derived from the *Aspergillus nidulans*  $P_{AlcA}$  promoter 5' of a minimal version of the human cytomegalovirus immediate early promoter (US Pat. No. 5,464,758), which controls expression of the human placental secreted alkaline phosphatase SEAP. The OP site is PCR-amplified from a  $P_{AlcA}$  containing vector (Genbank Accession No. S47331) using oligonucleotides OWW58 (5'-gatcgacgtcggagctaccatccaataaccc-3') and OWW59 (5'-gatccctgcaggccgctcggttggtgctct-3') and cloned (AatII/SbfI) into pWW37 (Weber et al., 2002. *Biotechnol Bioeng* 80, 691-705), thereby resulting in plasmid pWW192.

- 35 These constructs are used for gas-inducible expression of the reporter gene SEAP in Chinese hamster ovary cells (CHO-K1), baby hamster kidney cells (BHK-21) and human HeLa cells. These cell lines are seeded in 96-well plates (3 rows per cell line) and cotransfected with plasmids pWW192 and pWW195 using standard calcium phosphate

methods. The first wells in a row (WN 1) are supplemented with 24 µl/l acetaldehyde, and the plates are incubated in a humidified 5% CO<sub>2</sub>-containing atmosphere for 48 hours prior to quantification of SEAP production in all wells using a chemiluminescence kit from Roche (Roche Applied Science, Rotkreuz, Switzerland). The relative SEAP production in each well is shown in Figure 2. SEAP production is highest in acetaldehyde-containing wells and decreased in a distance-dependent manner for all three cell lines. Those results demonstrate, that the chimeric expression system based on *Aspergillus nidulans* genetic elements is (i) functional in different mammalian cell lines including human ones, (ii) enables inducible gene expression by addition of a liquid inducer acetaldehyde, and (iii) enables inducible gene expression by the gaseous inducer acetaldehyde, which diffuses through the gas phase to neighboring wells where it induces gene expression.

Example 2: Regulatable gene expression in mammalian cells induced by a complex gas mixture.

Acetaldehyde and related compounds are prevalent in complex gas mixtures like, for example, tobacco smoke. Tobacco smoke can be used to induce gene expression in mammalian cells harboring the genetic elements for gas-adjustable gene expression as described in Example 1.

CHO-K1 cells are transfected with plasmids pWW192 and pWW195 and exposed to different tobacco smoke concentrations in the culture atmosphere for 48 hours prior to quantification of SEAP production (Figure 3): SEAP expression gradually increases between 0.005% (v/v) smoke (0.06 ppm acetaldehyde) and 0.2% (v/v) smoke (2.4 ppm acetaldehyde), reaches a maximum expression plateau between 0.2% and 5% (v/v) smoke (60 ppm acetaldehyde) and collapses beyond 5% (v/v) tobacco smoke due to cell death associated with the undefined cytotoxic compound cocktail contained in tobacco smoke.

Example 3: Gas-inducible gene expression in animals.

The relative low toxicity of acetaldehyde (No Observable Effect Level: 152 ppm) predestinates this system for adjusting gene expression in non-human mammals in prototype gene therapy settings. CHO-K1 cells engineered for acetaldehyde-responsive gene expression (Example 1) are microencapsulated into alginate-poly-L-lysine-alginate microspheres using a droplet generator set to produce spheres of 400±50 µm in diameter, with each sphere containing 50-400 cells. 700 µl of capsule suspension (50% v/v) in MOPS-buffered physiological salt solution are intraperitoneally injected into mice, and the

mice kept in 100 l high-density polyethylene boxes (8 mice per box) sealed with paraffin. The boxes are filled with different tobacco smoke concentrations (smoke and air exchange in the boxes every 12 hours). After 72 hours serum is collected from the mice and activity of the reporter enzyme SEAP quantified using a chemiluminescence kit. The different SEAP levels (Figure 4) increase with increasing smoke concentrations and therefore show, that gas-inducible gene expression systems are able to titrate desired proteins in non-human mammals to specific levels.

10 Example 4: Viral vectors for transduction of mammalian cells with the gas-responsive gene expression system.

A retroviral vector is constructed for easy transduction of mammalian cells and non-human mammals with the acetaldehyde-responsive transcription factor AlcR. AlcR excised (EcoRI/SalI) from pAlcR is cloned (EcoRI/XhoI) into the pMSCV-derived (Mouse Stem Cell Virus, Clontech, Palo Alto, CA) vector pWW100 (Weber et al., 2002. *Biotechnol Bioeng* 80, 691-705) thereby resulting in vector pWW506. Retroviral particles are constructed by transient transfection of GP-293 cells (Clontech, Palo Alto, CA) with pWW506 according to the manufacturer's recommendations.

The responsive promoter containing the AlcR-specific OP site is PCR-amplified from plasmid pWW192 (Example 1) and ligated into the 3'-LTR sequence of a LTR<sub>ΔU3</sub> third-generation lentiviral vector (Mitta et al., 2002. *Nucleic Acids Res.* 30, e113). The lentiviral vector also contains a multiple cloning site for inserting any gene of interest and a neomycin-resistance gene for selection of transduced cells. Cotransfection of the vector construct together with the helper plasmids pLTR-G and pCD/NL-BH\* (Mitta et al., 2002. *Nucleic Acids Res.* 30, e113) into HEK 293-T cells produces viral particles, which are harvested from the supernatant and filtrated through a 0.45 µm low protein-binding filter. The viral particles can be readily used for transduction of any mammalian target cell or can be stored at -80°C.

30 Example 5: Gas-inducible gene expression in mammalian cells based on prokaryotic regulator proteins.

A regulatable expression system responsive to liquid or gaseous inducers based on bacterial elements is constructed by PCR-cloning the *Pseudomonas putida* (oleovorans)-derived RTF AlkS (Smiths et al., 2001. *Plasmid* 46, 16-24) into the mammalian expression vector pEF6/V5-His TOPO (Invitrogen, Carlsbad, CA). The responsive promoter is constructed by cloning 8 repeats of the AlkS-specific OP site downstream of the simian

virus 40 promoter  $P_{SV40}$  followed by a reporter gene, the secreted alkaline phosphatase SEAP.

- 5 Transfection of the plasmids encoding AlkS and the responsive promoter controlling SEAP expression in CHO-K1 cells results in SEAP expression levels typical for  $P_{SV40}$ -driven constitutive expression. However, upon addition of a cognate regulating compound (RC), like dicyclopropylketone, haloalkanes, ethyl acetate or ethyl ether, SEAP expression decreases in a dose-dependent manner, due to an RC-mediated interaction of AlkS with its cognate OP site leading to sterical hindrance of transcription.

Claims

1. A mammalian cell comprising
  - a. a responsive transcription factor RTF, which modulates transcription of OP operator-containing promoters in response to compounds being gaseous or liquid at the cultivation temperature of said mammalian cell;
  - b. a promoter or promoter fragments operatively linked to OP operator sites specific for binding of said RTF.
2. The mammalian cell of claim 1, wherein binding of the RTF to OP-containing promoters is changed in response to compounds being gaseous at the cultivation temperature of said mammalian cell.
3. The mammalian cell of claim 1, wherein binding of the RTF to OP-containing promoters is changed in response to compounds being liquid at the cultivation temperature of said mammalian cell.
4. The mammalian cell of claim 1, wherein the RTF comprises amino-acid sequences related to or derived from naturally occurring proteins.
5. The mammalian cell of claim 1, wherein the RTF is the *Aspergillus nidulans* AlcR protein.
6. The mammalian cell of claim 1, wherein the RTF is the *Pseudomonas putida* AlkS protein.
7. A non-human mammal comprising at least one mammalian cell as claimed in claim 1.
8. A method for adjusting the expression level of a protein in a mammalian cell as claimed in claim 1, comprising culturing said mammalian cell and modulating gene expression by administration of a compound for which transcription of the OP operator-containing promoter and the responsive transcription factor RTF are responsive.

9. The method of claim 8, wherein the protein is selected from the group consisting of SEAP, a fluorescent protein, human growth hormone, alpha-interferon, beta-interferon, gamma-interferon, insulin, erythropoietin, tissue plasminogen activator, DNase, a monoclonal antibody, Factor VIII, Factor VII, HAS, IL-2, glucagons, EGF, GCSF, GMCSF, thrombopoietin, gp160, HbSAg, a protein encoded by a tumor suppressor gene, and a protein encoded by a gene interfering with absorption, distribution, metabolism and excretion of compounds contained in tobacco smoke.
10. The method of claim 8, wherein the compound for modulating gene expression is selected from the group consisting of ketones, aldehydes, haloalkanes, alcohols, esters, amines, and ethers.
11. The method of claim 8 wherein the compound for modulating gene expression is selected from the group consisting of ethanol, methylamine, ethylamine, n-propylamine, n-butylamine, n-pentylamine, n-hexylamine, benzylamine, 2-butanone, ethanol, n-propanol, n-butanol, 2-propanol, 2-butanol, L-threonine, 2-methylbutyraldehyde, acetaldehyde, propanal, acetone, 2-butanone, 2-pentanone, 3-pentanone, cyclohexanone, glycoaldehyde, glyoxal, glyoxylate, ethylene glycol, ethanolamine, ethyl acetate, ethyl ether, and dicyclopropylketone.
12. An isolated nucleic acid useful for constructing a mammalian cell as claimed in claim 1, comprising an RTF functionally linked to a promoter useful for expression of the RTF in said mammalian cell.
13. The isolated nucleic acid of claim 12 comprising an OP sequence functionally linked to a promoter or a fragment thereof useful for RTF-dependent gene expression in said mammalian cell.
14. The isolated nucleic acid of claim 12 or 13 further comprising genetic elements useful for construction of viral vectors.

**Abstract**

The present invention discloses mammalian cells useful for regulated gene expression in response to compounds being gaseous or liquid at the cultivation temperature of said mammalian cell, and non-human mammals comprising such mammalian cells. The  
5 invention further discloses methods for producing proteins in mammalian cells in a regulated way in response to inducing gaseous or liquid compounds. The invention is further directed to isolated nucleic acids useful for constructing said mammalian cells.

FIG. 1






FIG. 2




FIG. 3





FIG. 4



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**